Affinage

WNT5A

Protein Wnt-5a · UniProt P41221

Length
380 aa
Mass
42.3 kDa
Annotated
2026-04-28
100 papers in source corpus 40 papers cited in narrative 41 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

WNT5A is a secreted glycoprotein that functions as a central ligand in β-catenin-independent (non-canonical) Wnt signaling, coordinating cell polarity, migration, invasion, immune modulation, and tissue homeostasis across diverse developmental and pathological contexts. WNT5A engages Frizzled family receptors (FZD2, FZD3, FZD5, FZD7) and co-receptors ROR1, ROR2, and RYK to activate multiple downstream cascades including PKC, JNK/c-Jun, RhoA (via DAAM1), Rac1, Ca²⁺/calcineurin, ERK, and Hippo/MST-LATS-YAP, with the specific output determined by receptor context (PMID:12086864, PMID:19720827, PMID:26690702, PMID:36622276). Through ROR2, WNT5A suppresses canonical Wnt/β-catenin signaling by disrupting β-catenin–TCF4 interaction, acting as a negative regulator of proliferation in hepatocytes and hematopoietic cells—where Wnt5a haploinsufficiency leads to myeloid leukemias and B-cell lymphomas—while simultaneously driving invasion, cytoskeletal reorganization, and pro-inflammatory cytokine production in melanoma, prostate cancer, CLL, and other malignancies (PMID:14667502, PMID:26100214, PMID:22344299, PMID:29648538). WNT5A also mediates intercellular communication in non-cancer contexts, including neuron-to-astrocyte signaling controlling astrogliosis and pain sensitization via ROR2/MMP2/IL-1β, microglial promotion of dendritic spine maturation, osteoblast-to-osteoclast precursor signaling via JNK/c-Jun–dependent RANK upregulation, renal AQP2 trafficking through calcineurin, vascular smooth muscle RhoA/ROCK activation in hypertension, and lysosomal cholesterol export through direct binding to NPC1 and NPC2 (PMID:35040478, PMID:36395958, PMID:22344299, PMID:27892464, PMID:32597829, PMID:34886684).

Mechanistic history

Synthesis pass · year-by-year structured walk · 20 steps
  1. 2002 High

    The first evidence that WNT5A activates a non-canonical PKC pathway to drive cancer invasion, establishing that WNT5A signals independently of β-catenin in melanoma through the receptor Frizzled-5.

    Evidence WNT5A overexpression in melanoma cells with Frizzled-5 blocking antibody; PKC activity and invasion assays

    PMID:12086864

    Open questions at the time
    • Identity of intermediates between Frizzled-5 and PKC not defined
    • No ROR co-receptor involvement tested at this point
  2. 2003 High

    WNT5A was identified as a tumor suppressor in hematopoietic tissue, demonstrating that the same ligand can have opposing roles (tumor suppressor vs. invasion promoter) depending on cell context.

    Evidence Wnt5a hemizygous mice developing myeloid leukemias and B-cell lymphomas; Ca²⁺ pathway suppression of cyclin D1

    PMID:14667502

    Open questions at the time
    • Receptor mediating tumor suppression not identified
    • Whether Ca²⁺ pathway is sufficient or necessary for suppression not fully dissected
  3. 2008 High

    WNT5A was shown to organize a novel intracellular polarity structure (W-RAMP) involving actin, myosin IIB, Frizzled-3, and MCAM, revealing how WNT5A translates signaling into directional cell movement through endosomal trafficking.

    Evidence Live cell imaging, dominant-negative GTPases (Rab4, RhoB), endosome trafficking inhibitors in melanoma cells

    PMID:18420933

    Open questions at the time
    • Upstream signal linking WNT5A receptor engagement to W-RAMP assembly not fully resolved
    • Generalizability beyond melanoma unknown
  4. 2009 High

    ROR2 was established as a key WNT5A receptor whose tyrosine kinase activity is required for inhibition of canonical Wnt/β-catenin signaling, confirmed by Ror2-null mice showing elevated canonical Wnt reporter activity.

    Evidence ROR2 domain/point mutagenesis with β-catenin reporter; Ror2 KO mice with Axin2(LacZ)

    PMID:19720827 PMID:19802008

    Open questions at the time
    • Direct kinase substrates of ROR2 upon WNT5A binding not identified
    • Whether kinase-dead ROR2 retains any non-canonical signaling capacity not tested
  5. 2010 High

    WNT5A was shown to drive cancer invasion through a defined Frizzled2/ROR2→PKD→JNK→JunD signaling cascade that transcriptionally activates MMP-1, providing a complete pathway from ligand to effector gene.

    Evidence ChIP for JunD at MMP-1 promoter, PKD inhibitors, JNK assays in prostate cancer cells

    PMID:20101234

    Open questions at the time
    • Relative contribution of ROR2 vs. Frizzled2 at receptor level not separated
    • Whether PKD activation requires direct ROR2 kinase activity unknown
  6. 2012 High

    A physiological WNT5A-ROR2 paracrine axis was demonstrated between osteoblasts and osteoclast precursors, where JNK/c-Jun activation transcriptionally upregulates RANK to sensitize precursors to RANKL-induced differentiation, linking WNT5A to bone remodeling.

    Evidence Cell-type-specific conditional knockouts, ChIP for c-Jun at RANK promoter, osteoclast differentiation assays

    PMID:22344299

    Open questions at the time
    • Whether WNT5A-ROR2 also modulates osteoblast differentiation through an autocrine mechanism not tested
  7. 2013 High

    WNT5A's role in axon guidance was mechanistically resolved: WNT5A calcium signaling activates CaMKII, which phosphorylates tau at Ser262 to detach it from microtubules and increase microtubule dynamics required for growth cone steering.

    Evidence Live MT imaging (EGFP-EB3), tau Ser262 mutant, CaMKII inhibitor, calcium imaging in cortical neurons

    PMID:23818454

    Open questions at the time
    • Receptor mediating WNT5A-calcium signaling in neurons not identified
    • Relevance in vivo during cortical wiring not tested
  8. 2013 Medium

    WNT5A was linked to cartilage matrix degradation through JNK/PCP-dependent upregulation of MMPs and ADAMTS5, and to cancer cell migration via DAAM1-RhoA, consolidating the RhoA branch of non-canonical signaling.

    Evidence JNK/PCP reporter assays, Daam1 pull-down, RhoA activation assays in glioblastoma and chondrocytes

    PMID:23474397 PMID:29207169

    Open questions at the time
    • Whether DAAM1 is universally required for WNT5A-RhoA in all cell types not established
    • Structural basis for DAAM1 activation by WNT5A receptors unknown
  9. 2015 High

    WNT5A was identified as a negative regulator of liver regeneration that suppresses β-catenin–TCF4 interaction and cyclin D1 through Frizzled-2, defining a tissue context where WNT5A actively antagonizes canonical Wnt signaling.

    Evidence Liver-specific Wntless and Wnt5a knockout mice, co-IP of β-catenin–TCF4, partial hepatectomy model

    PMID:26100214

    Open questions at the time
    • Mechanism by which Frizzled-2 uncouples β-catenin–TCF4 binding not defined
  10. 2016 High

    The ROR1–ROR2 heterooligomerization mechanism was dissected: WNT5A induces ROR1/ROR2 complex formation via the Kringle domain, which recruits GEFs to activate Rac1 and RhoA; separately, ROR1 phosphorylates cortactin to recruit ARHGEF1 and promote F-actin polymerization in CLL.

    Evidence Domain mutagenesis, Co-IP, GEF recruitment assays, Rac1/RhoA activation, cortactin phosphorylation at Y421, in vivo engraftment

    PMID:26690702 PMID:30568170

    Open questions at the time
    • Whether ROR1 kinase activity is direct or requires a co-kinase not fully resolved
    • Crystal structure of the ROR1-ROR2 complex unavailable
  11. 2016 High

    WNT5A was shown to suppress rDNA transcription by Pol I through DVL1 accumulation at nucleolar organizer regions, displacing SIRT7 from rDNA, revealing a nuclear transcriptional function for non-canonical Wnt signaling.

    Evidence ChIP, Co-IP, rDNA transcription assays, DVL1 nuclear imaging, siRNA in breast cancer cells

    PMID:27500936

    Open questions at the time
    • Mechanism of DVL1 nuclear import not defined
    • Whether this function operates in non-cancer cells unknown
  12. 2016 High

    WNT5A was connected to a vasopressin-independent renal water balance mechanism: WNT5A induces AQP2 expression, phosphorylation, and apical trafficking via calcineurin, rescuing urine-concentrating ability in nephrogenic diabetes insipidus mice.

    Evidence AQP2 trafficking assays, calcineurin inhibitor experiments, NDI mouse model urine osmolality

    PMID:27892464

    Open questions at the time
    • Receptor(s) mediating calcineurin activation in collecting duct cells not identified
    • Long-term efficacy and safety of WNT5A pathway activation in NDI not assessed
  13. 2017 High

    A complete WNT5A→ROR2→RhoA→PKN3→c-Src signaling cascade was mapped in osteoclasts, showing that PKN3 binds and activates c-Src for actin ring formation and bone resorption, validated by double-KO phenotypes.

    Evidence Conditional Ror2 and global Pkn3 KO mice, Co-IP of PKN3 with c-Src, kinase assays, constitutively active RhoA rescue

    PMID:28851822

    Open questions at the time
    • Whether PKN3 is recruited directly by active RhoA or via an intermediate not resolved
    • Pharmacological targeting of PKN3 not tested
  14. 2018 High

    WNT5A was shown to regulate the depalmitoylation machinery: WNT5A phosphorylates APT1, which increases its depalmitoylation activity toward CD44 and MCAM, promoting melanoma invasion through altered membrane protein dynamics.

    Evidence Phosphorylation assays, depalmitoylation activity, dimerization assays, invasion assays in melanoma cells

    PMID:29648538

    Open questions at the time
    • Kinase directly phosphorylating APT1 downstream of WNT5A not identified
    • Whether other palmitoylated substrates are affected not tested
  15. 2019 High

    An autocrine WNT5A survival loop was defined in CLL: STAT3 transcriptionally activates WNT5A, which signals through ROR1 to activate Rac1 and NF-κB (via DVL2/Akt/TRAF2/RIP), sustaining cell survival and cytokine secretion.

    Evidence ChIP + EMSA for STAT3 at WNT5A promoter, Rac1 activation assays, NF-κB reporter, WNT5A siRNA apoptosis

    PMID:27904138 PMID:31510045 PMID:31645416

    Open questions at the time
    • Whether STAT3-WNT5A transcriptional axis operates in solid tumors not determined
    • Relative contribution of ROR1 vs. ROR2 to NF-κB activation not separated
  16. 2020 High

    WNT5A was positioned in vascular biology as both a hypertension mediator (through RhoA/ROCK in VSMCs under Klotho deficiency) and an alveologenesis regulator (through PCP/Vangl2), demonstrating tissue-specific developmental and pathological functions.

    Evidence VSMC-specific Wnt5a siRNA, Klotho KO mice, blood pressure measurement; epithelial and myofibroblast conditional KO for alveologenesis

    PMID:32394892 PMID:32597829

    Open questions at the time
    • Direct mechanism linking Klotho to WNT5A expression/activity not fully defined
    • Whether Vangl2 acts as a co-receptor or downstream effector in alveolar cells not distinguished
  17. 2021 High

    WNT5A was discovered to directly bind NPC1 and NPC2 and function in lysosomal cholesterol export machinery, linking WNT5A to lipid metabolism beyond its canonical role as a signaling ligand; Wnt5a deletion in VSMCs disrupted lysosomal function and promoted atherosclerosis.

    Evidence Co-IP with NPC1/NPC2, CRISPR KO in human VSMCs, VSMC-specific Wnt5a KO mice, cholesterol trafficking assays

    PMID:34886684

    Open questions at the time
    • Whether WNT5A acts inside lysosomes or at the lysosomal membrane not determined
    • Structural basis for WNT5A–NPC1/NPC2 interaction unknown
  18. 2021 High

    RNF43 was identified as a negative regulator of WNT5A non-canonical signaling: it ubiquitinates VANGL2 for proteasomal degradation and triggers clathrin-dependent internalization of ROR1, providing a defined turnoff mechanism for the pathway.

    Evidence BioID interactome, ubiquitination assays, proteasome and clathrin inhibitors, in vivo melanoma models

    PMID:34702444

    Open questions at the time
    • Whether RNF43 ubiquitinates ROR2 directly not tested
    • Regulation of RNF43 expression in non-canonical Wnt contexts not explored
  19. 2022 High

    A neuron-to-astrocyte WNT5A-ROR2 paracrine axis was established as essential for astrogliosis in both HIV-associated and morphine-induced pain, activating MMP2/inflammasome/IL-1β to rewire spinal neural circuits.

    Evidence Conditional neuronal Wnt5a and astrocytic Ror2 KO, behavioral hyperalgesia assays, circuit polarization analysis

    PMID:35040478 PMID:36203006

    Open questions at the time
    • Whether other WNT ligands compensate in WNT5A-deficient neurons not tested
    • Downstream signaling from ROR2 to MMP2 in astrocytes not fully mapped
  20. 2023 High

    WNT5A-ROR2 was connected to Hippo pathway regulation: in ROR2-positive cells, WNT5A activates MST1/2-LATS-YAP phosphorylation to suppress tumor growth, while in ROR2-negative cells it suppresses Hippo via NF2/Merlin phosphorylation, establishing receptor-dependent pathway switching.

    Evidence MST1/2 deletion, Hippo phosphorylation cascades, prostate cancer organoids and xenografts, ROR2+/− comparison

    PMID:36622276

    Open questions at the time
    • Direct kinase linking ROR2 to MST1/2 activation not identified
    • Whether other Wnt ligands can similarly engage Hippo not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key open questions include: how receptor availability (FZD, ROR1, ROR2) is coordinated to determine pathway choice in a given cell; the structural basis of WNT5A–receptor complexes; and whether the newly discovered lysosomal cholesterol export function of WNT5A operates independently of classical receptor signaling.
  • No crystal structure of WNT5A bound to any receptor complex
  • Mechanism of context-dependent pathway switching between tumor suppression and invasion not resolved at the molecular level
  • Whether intracellular/lysosomal WNT5A functions require secretion and receptor re-engagement is unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 10 GO:0060089 molecular transducer activity 4 GO:0098772 molecular function regulator activity 4
Localization
GO:0005576 extracellular region 9 GO:0031410 cytoplasmic vesicle 2 GO:0005764 lysosome 1
Pathway
R-HSA-162582 Signal Transduction 13 R-HSA-1643685 Disease 10 R-HSA-112316 Neuronal System 4 R-HSA-168256 Immune System 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 2 R-HSA-1500931 Cell-Cell communication 2
Partners
DAAM1DVL1FZD2FZD5NPC1NPC2ROR1ROR2

Evidence

Reading pass · 41 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 WNT5A overexpression in melanoma cells causes actin reorganization, increased cell adhesion, and increased PKC activation without increasing β-catenin expression or nuclear translocation; blocking the WNT5A receptor Frizzled-5 inhibited PKC activity and cellular invasion, placing WNT5A upstream of PKC in a non-canonical pathway driving melanoma invasiveness. Constitutive overexpression of WNT5A in melanoma cell lines, antibody blocking of Frizzled-5, PKC activity assays, invasion assays Cancer Cell High 12086864
2009 ROR2 requires tyrosine kinase activity to mediate WNT5A signaling; mutation/deletion analysis showed that specific domains and residues in ROR2, including those necessary for kinase activity, are required for WNT5A-mediated inhibition of canonical Wnt/β-catenin signaling; Ror2-null mice show increased Axin2(LacZ) reporter activity, confirming Ror2 inhibits canonical Wnt signaling in vivo. Deletion and point mutagenesis of ROR2 domains, β-catenin reporter assays, Ror2 knockout mice with Axin2(LacZ) reporter Journal of Biological Chemistry High 19720827
2009 ROR2 is a receptor for WNT5A in melanoma; WNT5A increases ROR2 expression and induces PKC-dependent, clathrin-mediated internalization of ROR2; siRNA knockdown of WNT5A decreases ROR2 expression, while ROR2 knockdown decreases downstream WNT5A signaling and inhibits WNT5A-mediated melanoma metastasis in vitro and in vivo. siRNA knockdown, in vitro and in vivo metastasis assays, tissue microarray, receptor internalization studies Oncogene High 19802008
2008 WNT5A controls cell polarity and directional movement in melanoma by recruiting actin, myosin IIB, Frizzled 3, and melanoma cell adhesion molecule (MCAM) into a Wnt-mediated receptor-actin-myosin polarity (W-RAMP) intracellular structure; this process requires endosome trafficking associated with multivesicular bodies and is regulated by WNT5A through small GTPases Rab4 and RhoB. Live cell imaging, fluorescence microscopy, dominant-negative GTPases, endosome trafficking inhibitors, chemokine gradient assays Science High 18420933
2010 WNT5A promotes prostate cancer invasion through Frizzled2 and ROR2 as receptors, activating JNK via protein kinase D (PKD); PKD inhibition suppressed WNT5A-dependent cell migration and invasion; WNT5A induced metalloproteinase-1 (MMP-1) expression through recruitment of JunD to its promoter. Knockdown and overexpression of WNT5A, PKD inhibitors, JNK signaling assays, ChIP for JunD at MMP-1 promoter, invasion assays Oncogene High 20101234
2012 WNT5A expressed by osteoblast-lineage cells signals through ROR2 expressed on osteoclast precursors to enhance osteoclastogenesis; WNT5A-ROR2 activates JNK and recruits c-Jun to the RANK gene promoter, increasing RANK expression and thus sensitizing precursors to RANKL-induced osteoclastogenesis; mice deficient in either Wnt5a or Ror2 show impaired osteoclastogenesis. Cell-type-specific conditional knockouts, JNK activation assays, ChIP for c-Jun at RANK promoter, osteoclast differentiation assays, arthritis mouse models Nature Medicine High 22344299
2003 WNT5A signals through the noncanonical Wnt/Ca2+ pathway to suppress cyclin D1 expression and negatively regulate B cell proliferation; Wnt5a hemizygous mice develop myeloid leukemias and B cell lymphomas with loss of Wnt5a function in tumor tissues, identifying Wnt5a as a tumor suppressor in hematopoietic tissue. Wnt5a knockout/hemizygous mice, cell proliferation assays, cyclin D1 western blot, Ca2+ pathway signaling assays Cancer Cell High 14667502
2016 WNT5A induces ROR1 to oligomerize with ROR2, which recruits guanine exchange factors (GEFs) that activate Rac1 and RhoA to promote CLL cell proliferation and chemokine-directed migration; the extracellular Kringle domain is required for ROR1/ROR2 heterooligomerization, and the cysteine-rich domain or intracellular proline-rich domain is required for GEF recruitment. Co-immunoprecipitation, ectopic expression of ROR1/ROR2 mutants, GEF recruitment assays, Rac1/RhoA activation assays, in vivo engraftment in immune-deficient mice Journal of Clinical Investigation High 26690702
2017 WNT5A signaling through ROR2 promotes bone resorption by activating RhoA (a small GTPase); Rho effector kinase PKN3 then binds to and enhances c-Src activity, which is critical for actin ring formation in osteoclasts; osteoclast-specific Ror2-deficient mice and global Pkn3-deficient mice both show increased bone mass and impaired bone resorption. Conditional and global knockout mice, co-immunoprecipitation of PKN3 with c-Src, kinase activity assays, actin ring formation assays, constitutively active RhoA rescue experiments Science Signaling High 28851822
2016 WNT5A causes ROR1 to complex with and phosphorylate cortactin at Y421; phosphorylated cortactin recruits ARHGEF1 and activates RhoA, enhancing CLL cell migration; the proline-rich domain of ROR1, specifically position P841, is required for cortactin binding and subsequent F-actin polymerization. Co-immunoprecipitation, ROR1 domain mutagenesis (single amino acid substitutions), cortactin phosphorylation assays, F-actin polymerization assays, migration assays Leukemia High 30568170
2018 WNT5A signaling results in APT1 (acyl protein thioesterase 1) phosphorylation which increases APT1 depalmitoylating activity and reduces APT1 dimerization; APT1-mediated depalmitoylation of CD44 and MCAM promotes melanoma invasion. Phosphorylation assays, depalmitoylation activity assays, dimerization assays, in vitro invasion assays, phospho-specific analysis eLife High 29648538
2016 WNT5A signals through Dishevelled1 (DVL1) to suppress rDNA transcription by RNA Polymerase I in breast cancer cells; DVL1 accumulates at nucleolar organizer regions (NORs) and binds rDNA, causing SIRT7 to release from rDNA loci and disassembly of Pol I transcription machinery at the rDNA promoter. ChIP, co-immunoprecipitation, rDNA transcription assays, DVL1 nuclear localization imaging, siRNA knockdown PLoS Genetics High 27500936
2016 WNT5A induces renal AQP2 expression, phosphorylation, and apical membrane trafficking via calcineurin signaling, bypassing the vasopressin/cAMP/PKA pathway; this WNT5A-calcineurin axis increases urine osmolality in a nephrogenic diabetes insipidus (NDI) mouse model. AQP2 phosphorylation and trafficking assays, calcineurin inhibitor experiments, urine osmolality measurement in NDI mouse model, in vitro cell assays Nature Communications High 27892464
2019 WNT5A transported by exosomes activates non-canonical signaling in human cardiac fibroblasts, including phosphorylation of ERK1/2 and JNK and stimulation of IL-6 production, but does not activate β-catenin-dependent signaling, in contrast to WNT3a-containing exosomes which activate canonical signaling. Exosome isolation and characterization, β-catenin reporter assays, ERK/JNK phosphorylation western blot, IL-6 ELISA, exosome marker characterization International Journal of Molecular Sciences Medium 30901906
2013 WNT5A promotes glioblastoma cell invasion via the Daam1/RhoA signaling pathway; WNT5A activates Daam1 and RhoA (but not Cdc42 or Rac1) to promote stress fiber formation and invasion; Daam1 siRNA or RhoA inhibitor abolished WNT5A-induced invasion without affecting proliferation. Pull-down assays for Daam1 activation, small G-protein activation assays for RhoA/Rac1/Cdc42, siRNA knockdown, RhoA inhibitor treatment, invasion assays Oncology Reports Medium 29207169
2013 WNT5A promotes Ewing sarcoma cell migration by upregulating CXCR4 expression via the JNK/c-Jun pathway; WNT5A shRNA and JNK inhibitor both reduced CXCR4 expression and cell migration, and SFRP5 (an antagonist that directly binds WNT5A) suppressed these effects. shRNA knockdown, recombinant WNT5A treatment, JNK inhibitor, migration assays, CXCR4 expression analysis BMC Cancer Medium 23075330
2015 WNT5A inhibits hepatocyte proliferation and concludes liver regeneration by acting as a negative regulator of β-catenin signaling through the Frizzled-2 receptor; exogenous WNT5A decreased β-catenin-TCF4 interaction, cyclin D1 expression, and cell proliferation in primary hepatocytes and liver tumor cells. Liver-specific Wntless (Wls) knockout mice, Wnt5a liver-specific knockout, exogenous WNT5A treatment of primary hepatocytes, co-immunoprecipitation of β-catenin-TCF4, cyclin D1 western blot, partial hepatectomy model American Journal of Pathology High 26100214
2013 WNT5A is required for cortical axon outgrowth and repulsive guidance through calcium signaling and tau-mediated reorganization of dynamic microtubules; WNT5A increases axon outgrowth by reorganizing dynamic MTs from splayed to bundled arrays; CaMKII phosphorylates tau at Ser262, detaching tau from MTs to increase dynamics required for growth cone steering; mutation of the Ser262 site abolished WNT5A-induced axon outgrowth and repulsion. Live cell imaging of EGFP-EB3 labeled MTs, tau Ser262 mutant transfection, CaMKII inhibitor, nocodazole/taxol MT dynamics inhibitors, calcium imaging Developmental Neurobiology High 23818454
2020 A WNT5A-ROR2-Vangl2 cascade in the planar cell polarity (PCP) pathway is required for alveologenesis in mammalian lungs; this axis confers cellular properties including PDGF secretion from alveolar epithelial cells, type I cell shape changes, and myofibroblast migration through cytoskeletal reorganization. Conditional knockout mice (epithelial and myofibroblast-specific), cytoskeletal analysis, PDGF secretion assays, cell shape and migration quantification eLife High 32394892
2021 RNF43, an E3 ubiquitin ligase, inhibits WNT5A-driven noncanonical signaling by interacting with ROR1, ROR2, VANGL1, and VANGL2; RNF43 triggers VANGL2 ubiquitination and proteasomal degradation and clathrin-dependent internalization of ROR1, and inhibits ROR2 activation, thereby blocking WNT5A-mediated melanoma invasion. BioID interactome, co-immunoprecipitation, ubiquitination assays, proteasome inhibitor treatment, clathrin inhibition, invasion assays, in vivo melanoma models eLife High 34702444
2019 WNT5A activates the NF-κB pathway in melanoma via ROR1, Dvl2, and Akt (from WNT5A pathway) converging on TRAF2 and RIP (from NF-κB pathway); this induces p65 phosphorylation, IKK phosphorylation, IκB degradation, nuclear translocation of p65, and secretion of IL-6, IL-8, IL-11, MCP-1, and TNF-sRI; an autocrine WNT5A loop maintains constitutive NF-κB activity. cDNA overexpression, siRNA knockdown, dominant negative mutants, NF-κB reporter assays, cytokine/chemokine secretion assays, phosphorylation western blots Cells Medium 31510045
2023 WNT5A signaling through ROR2 activates the Hippo pathway to suppress YAP1 activity and tumor growth; WNT5A caused ROR2-dependent increased phosphorylation of MST1/2, LATS1, MOB1, and YAP1; deletion of MST1/2 abrogated the WNT5A response; in ROR2-negative cells, WNT5A instead suppressed Hippo via increased inhibitory phosphorylation of NF2/Merlin; YAP1 activity also positively regulates ROR2 and WNT5A, forming a negative feedback loop. Prostate cancer organoid and xenograft models, MST1/2 deletion, Hippo pathway phosphorylation western blots, ROR2-expressing vs ROR2-negative cell comparison, clinical dataset correlation Cancer Research High 36622276
2020 WNT5A deficiency under Klotho deficiency promotes salt-sensitive hypertension via non-canonical WNT5A/RhoA signaling in vascular smooth muscle cells; WNT5A and angiotensin II (Ang II) increase RhoA activity (measured by p-MYPT1); siRNA knockdown of WNT5A abolishes Ang II-induced Rho/ROCK activation, and Klotho supplementation inhibits WNT5A-mediated p-MYPT1 upregulation. Wnt5a siRNA in cultured VSMCs, Klotho knockout and supplementation mice, blood pressure measurement, renal blood flow assays, p-MYPT1 as RhoA activity readout Journal of Clinical Investigation High 32597829
2019 WNT5A signals through ROR1 to activate Rac1 in CLL cells, promoting cell proliferation and survival; ibrutinib (BTK inhibitor) does not block this WNT5A-ROR1-Rac1 axis; the anti-ROR1 mAb cirmtuzumab blocks WNT5A-induced Rac1 activation and enhances ibrutinib activity in vivo. Rac1 activation assays, CLL cell proliferation assays, in vivo leukemia clearance models, ibrutinib + cirmtuzumab combination treatment Leukemia Medium 27904138
2019 STAT3 binds to the WNT5A gene promoter and transcriptionally activates WNT5A expression in CLL cells; STAT3 shRNA downregulates WNT5A mRNA and protein; WNT5A and its receptor ROR1 are co-expressed on CLL cell surface; WNT5A siRNA increases spontaneous apoptosis of CLL cells, indicating an autocrine survival loop. ChIP, EMSA, luciferase reporter assay for STAT3-WNT5A promoter interaction, STAT3 shRNA, WNT5A siRNA, apoptosis assays, flow cytometry Journal of Immunology High 31645416
2021 WNT5A is a crucial component of the lysosomal cholesterol export machinery; it increases lysosomal acid lipase expression, decreases mTORC1 signaling, and physically binds to NPC1 and NPC2 to promote lysosomal cholesterol egress to the endoplasmic reticulum; Wnt5a deletion in vascular smooth muscle cells disrupts lysosomal function and promotes atherosclerosis. Vascular smooth muscle cell-specific Wnt5a knockout mice, CRISPR/Cas9 knockout of WNT5A in human VSMCs, co-immunoprecipitation with NPC1/NPC2, lysosomal acid lipase assays, mTORC1 activity assays, cholesterol trafficking assays Circulation Research High 34886684
2017 WNT5A in cardiac fibroblasts activates ERK1/2 signaling (without affecting β-catenin levels) to induce dose-dependent upregulation and release of IL-6 and TIMP-1; ERK1/2 inhibition attenuates WNT5A-induced IL-6 and TIMP-1 release. Recombinant WNT5A treatment of primary mouse and human cardiac fibroblasts, ERK1/2 inhibitor, western blot, cytokine measurement Journal of Molecular Medicine Medium 28357477
2022 A neuron-to-astrocyte WNT5A-ROR2 signaling axis controls astrogliosis in HIV-associated pain; conditional knockout of WNT5A in neurons or ROR2 in astrocytes abolished gp120-induced astrogliosis, hyperalgesia, and neural circuit polarization; the astrogliosis promotes IL-1β expression via a WNT5A-ROR2-MMP2 axis. Conditional neuronal Wnt5a knockout, conditional astrocytic Ror2 knockout, behavioral pain assays, spinal cord circuit analysis Brain High 35040478
2022 Morphine-induced astrogliosis requires WNT5A signaling from neurons to astrocytes via ROR2; conditional knockout of neuronal Wnt5a or astrocytic Ror2 blocked morphine-induced astrogliosis, opioid-induced hyperalgesia, and neural circuit polarization; the WNT5A-ROR2 astrogliosis promotes OIH via inflammasome-regulated IL-1β. Conditional neuronal Wnt5a and astrocytic Ror2 knockouts, opioid-induced hyperalgesia behavioral assays, neural circuit polarization analysis, inflammasome/IL-1β measurement Molecular Psychiatry High 36203006
2019 WNT5A signals through ROR1 and ROR2 to activate RhoA (via DAAM1) in esophageal squamous cell carcinoma; ROR1 and ROR2 form a complex in ESCC cells; DAAM1 is required for RhoA activation downstream of ROR1/ROR2, and a RhoA inhibitor blocks invasion but not DAAM1 activity. Anti-ROR1 antibody, ROR2 shRNA, DAAM1 shRNA, RhoA inhibitor, Rho activation assays, co-immunoprecipitation of ROR1-ROR2, invasion assays, actin filament staining Cancer Management and Research Medium 31114334
2022 Microglial WNT5A is the most abundantly expressed WNT in microglia and promotes neuronal dendritic spine maturation and synaptic density; silencing microglial Wnt5a in co-culture with neurons reduces spine density, reduces PSD95 and synaptic density, and significantly decreases neuronal firing rate. Neuron-microglia co-culture, Wnt5a siRNA knockdown in microglia, confocal imaging of dendritic spines and synaptic markers, multiple electrode array recording Brain, Behavior, and Immunity Medium 36395958
2019 WNT5A/ROR2 pathway promotes cholesterol accumulation and inflammatory response in vascular smooth muscle cells by inhibiting ABCA1 expression; Wnt5a overexpression inhibited ABCA1, impaired cholesterol efflux, facilitated NF-κB nuclear translocation, and promoted inflammatory cytokine secretion; ROR2 knockdown reversed these effects. Wnt5a overexpression and knockdown, ROR2 knockdown, ABCA1 expression assays, cholesterol efflux assays, NF-κB nuclear translocation assays, ApoE-/- mouse model Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids Medium 31678514
2018 WNT5A induces castration-resistant prostate cancer via CCL2; WNT5A-induced CCL2 expression is mediated by the MAPK/ERK signaling pathway; in vivo, WNT5A overexpression promoted castration resistance which was inhibited by macrophage depletion, indicating WNT5A drives CRPC via macrophage recruitment through CCL2. Doxycycline-inducible WNT5A overexpression, MAPK/ERK pathway inhibitors, CCL2 ELISA, clodronate liposome macrophage depletion, in vivo castration resistance model British Journal of Cancer Medium 29381686
2019 WNT5A promotes ESCC and glioblastoma invasion; in glioblastoma, WNT5A specifically activates RhoA (not Rac1) downstream of ROR1/ROR2 and DAAM1 to promote actin stress fiber formation and invasion. Small G-protein activation assays, DAAM1 pull-down, ROR1/2 and DAAM1 siRNA, invasion assays Cancer Management and Research Medium 31114334
2023 PRMT2-mediated asymmetric dimethylation of H3R8 (H3R8me2a) at the WNT5A promoter region enhances WNT5A transcriptional expression, thereby activating Wnt signaling and promoting RCC cell proliferation and metastasis. ChIP for H3R8me2a at WNT5A promoter, PRMT2 overexpression and knockdown, WNT5A expression assays, in vitro and in vivo proliferation/metastasis assays Cell Death and Disease Medium 37173306
2020 PGC1α silencing (via H3K27me3 promoter methylation) activates TCF12, which increases WNT5A expression; WNT5A in turn stabilizes YAP protein levels to promote melanoma migration and metastasis; inhibition of TCF12, WNT5A, or YAP blocked melanoma migration in vitro and metastasis in vivo. EZH2 inhibitor, PGC1α and TCF12 genetic manipulation, WNT5A knockdown, YAP protein stability assays, in vitro migration and in vivo metastasis assays Journal of Clinical Investigation High 31929186
2021 Cardiac WNT5A and WNT11 promote cardiac fibrosis by activation of the crosstalk between FZD5 and EGFR; exogenous WNT5A activated ERK and p38, promoted EGFR phosphorylation, and increased FZD5 expression in cardiac fibroblasts; FZD5 knockdown suppressed WNT5A-induced EGFR phosphorylation and pro-fibrotic effects, and EGFR inhibition attenuated FZD5 upregulation. TAC mouse model, shRNA knockdown of Wnt5a and Wnt11, exogenous WNT5A treatment of cardiac fibroblasts, EGFR and FZD5 siRNA, ERK/p38/EGFR phosphorylation western blots Cell Death and Disease Medium 34564708
2013 WNT5A-conditioned medium inhibits canonical Wnt signaling and strongly activates JNK/PCP signaling in mandibular chondrocytes; excess WNT5A stimulates cartilage matrix degradation through non-canonical JNK pathway by upregulating MMP1, MMP13, and ADAMTS5; JNK antagonism (but not DKK1) partially rescued the WNT5A-induced matrix loss phenotype. Luciferase reporter assays for canonical and JNK/PCP pathways, Marimastat MMP/aggrecanase inhibitor, DKK1 canonical pathway inhibitor, JNK small molecule antagonist, mandibular micromass cultures, in vivo retroviral overexpression Matrix Biology Medium 23474397
2022 Myeloid-derived suppressor cells (MDSCs) are a major source of WNT5A in the melanoma tumor microenvironment; myeloid-specific WNT5A knockdown decreased MDSC and Treg infiltration, reduced MDSC immunosuppressive activity (TGFβ1, arginase 1), decreased lung metastasis, and reduced PD-1/LAG3 expression on tumor-infiltrating lymphocytes. Myeloid-specific WNT5A knockdown (in vivo), flow cytometry for immune cell populations and exhaustion markers, TGFβ1/arginase 1 measurement, lung metastasis quantification Cancer Research Medium 33262126
2019 WNT5A upregulates ABCG2 expression in pancreatic cancer cells through FZD7 receptor signaling; FZD7 siRNA or inhibitors blocked WNT5A-induced ABCG2 upregulation and attenuated WNT5A-induced gemcitabine resistance. Recombinant WNT5A treatment, FZD7 siRNA, FZD7 inhibitors, ABCG2 expression assays, gemcitabine resistance assays Molecular Medicine Reports Medium 33200805
2019 WNT5A induces MCP-1 expression in gastric cancer cells via IL-1β, which in turn promotes macrophage chemotaxis and cytoskeletal changes; IL-1 receptor antagonist suppressed WNT5A-conditioned medium-induced macrophage migration. WNT5A overexpression vector, WNT5A siRNA, IL-1β ELISA, MCP-1 expression assay, macrophage transwell migration, FITC-phalloidin cytoskeleton staining, IL-1Ra treatment BMC Cancer Medium 24993819

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer cell 735 12086864
2012 Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nature medicine 421 22344299
2003 Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development (Cambridge, England) 327 12538525
2003 Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer cell 279 14667502
2011 Wnt5a: its signalling, functions and implication in diseases. Acta physiologica (Oxford, England) 267 21518267
2010 Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 196 20101234
2009 WNT5A is a regulator of fibroblast proliferation and resistance to apoptosis. American journal of respiratory cell and molecular biology 196 19251946
2008 Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science (New York, N.Y.) 193 18420933
2022 Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer cell 183 36459995
2009 The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene 164 19802008
2016 Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. The Journal of clinical investigation 160 26690702
2015 WNT-5A: signaling and functions in health and disease. Cellular and molecular life sciences : CMLS 152 26514730
2010 Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends in cell biology 151 20359892
2009 Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. The Journal of biological chemistry 138 19720827
2008 WNT5A expression increases during melanoma progression and correlates with outcome. Clinical cancer research : an official journal of the American Association for Cancer Research 136 18794093
2006 Increased expression of Wnt5a in psoriatic plaques. The Journal of investigative dermatology 135 16858420
1995 Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 131 9815976
2008 Wnt5a is expressed in murine and human atherosclerotic lesions. American journal of physiology. Heart and circulatory physiology 122 18456733
2007 Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 117 17486081
2007 Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer letters 87 17709179
2008 Wnt4 and Wnt5a promote adipocyte differentiation. FEBS letters 86 18708054
2017 Role of Wnt5a in the Pathogenesis of Inflammatory Diseases. Journal of cellular physiology 85 27859213
2014 Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders. Atherosclerosis 85 25240110
2011 Wnt5a regulates growth, patterning, and odontoblast differentiation of developing mouse tooth. Developmental dynamics : an official publication of the American Association of Anatomists 81 21246660
2016 Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. Leukemia 74 27904138
2014 Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. Journal of cellular physiology 74 24464650
2019 WNT3a and WNT5a Transported by Exosomes Activate WNT Signaling Pathways in Human Cardiac Fibroblasts. International journal of molecular sciences 68 30901906
2017 Wnt5a induces catabolic signaling and matrix metalloproteinase production in human articular chondrocytes. Osteoarthritis and cartilage 62 28587781
2018 WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. British journal of cancer 61 29381686
2020 Salt causes aging-associated hypertension via vascular Wnt5a under Klotho deficiency. The Journal of clinical investigation 60 32597829
2017 Protein kinase N3 promotes bone resorption by osteoclasts in response to Wnt5a-Ror2 signaling. Science signaling 60 28851822
2007 Wnt1 and Wnt5a affect endothelial proliferation and capillary length; Wnt2 does not. Growth factors (Chur, Switzerland) 60 17454147
2017 Wnt5a is elevated in heart failure and affects cardiac fibroblast function. Journal of molecular medicine (Berlin, Germany) 59 28357477
2017 Wnt5a and its signaling pathway in angiogenesis. Clinica chimica acta; international journal of clinical chemistry 56 28641961
2017 Wnt5a Signaling in Normal and Cancer Stem Cells. Stem cells international 55 28491097
2016 Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway. Nature communications 53 27892464
2013 Dual functions for WNT5A during cartilage development and in disease. Matrix biology : journal of the International Society for Matrix Biology 52 23474397
2018 Wnt5a suppresses inflammation-driven intervertebral disc degeneration via a TNF-α/NF-κB-Wnt5a negative-feedback loop. Osteoarthritis and cartilage 47 29656141
2020 Wnt5a Signaling in Gastric Cancer. Frontiers in cell and developmental biology 46 32195251
2016 Biological functions of macrophage-derived Wnt5a, and its roles in human diseases. Oncotarget 46 27608847
2012 Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression. BMC cancer 43 23075330
2014 Overexpression of Wnt5a promotes angiogenesis in NSCLC. BioMed research international 42 24999479
2022 WNT5A in tumor development and progression: A comprehensive review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 40 36089446
2020 H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP. The Journal of clinical investigation 40 31929186
2018 Wnt5a signaling induced phosphorylation increases APT1 activity and promotes melanoma metastatic behavior. eLife 40 29648538
2014 Expression of Wnt-5a and β-catenin in primary hepatocellular carcinoma. International journal of clinical and experimental pathology 40 25031739
2013 Wnt5a evokes cortical axon outgrowth and repulsive guidance by tau mediated reorganization of dynamic microtubules. Developmental neurobiology 40 23818454
2023 WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer research 39 36622276
2011 Wnt5a as an effector of TGFβ in mammary development and cancer. Journal of mammary gland biology and neoplasia 39 21416313
2007 Expression of Wnt5a and its downstream effector beta-catenin in uveal melanoma. Melanoma research 39 17992121
2020 A mammalian Wnt5a-Ror2-Vangl2 axis controls the cytoskeleton and confers cellular properties required for alveologenesis. eLife 38 32394892
2014 Challenging role of Wnt5a and its signaling pathway in cancer metastasis (Review). Experimental and therapeutic medicine 37 24944588
2021 RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. eLife 36 34702444
2017 Daam1 activates RhoA to regulate Wnt5a‑induced glioblastoma cell invasion. Oncology reports 36 29207169
2024 Single-Cell RNA Sequencing Reveals Dysregulated POSTN+WNT5A+ Fibroblast Subclusters in Prurigo Nodularis. The Journal of investigative dermatology 35 38246584
2013 Wnt5a inhibits the proliferation and melanogenesis of melanocytes. International journal of medical sciences 35 23569434
2013 Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiation. Blood 35 23660959
2019 An Autocrine Wnt5a Loop Promotes NF-κB Pathway Activation and Cytokine/Chemokine Secretion in Melanoma. Cells 34 31510045
2018 Ibrutinib inhibition of ERBB4 reduces cell growth in a WNT5A-dependent manner. Oncogene 34 29398709
2018 Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. Leukemia 34 30568170
2015 miR-217 targeting Wnt5a in osteosarcoma functions as a potential tumor suppressor. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 34 26054690
2018 Role of wnt5a in Metabolic Inflammation in Humans. The Journal of clinical endocrinology and metabolism 33 30137542
2019 Wnt5a/Ror2 pathway contributes to the regulation of cholesterol homeostasis and inflammatory response in atherosclerosis. Biochimica et biophysica acta. Molecular and cell biology of lipids 30 31678514
2015 WNT5A inhibits hepatocyte proliferation and concludes β-catenin signaling in liver regeneration. The American journal of pathology 30 26100214
2013 Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C. PloS one 30 23349696
2021 Cardiac Wnt5a and Wnt11 promote fibrosis by the crosstalk of FZD5 and EGFR signaling under pressure overload. Cell death & disease 29 34564708
2015 Non-canonical WNT5A is a potential regulator of granulosa cell function in cattle. Molecular and cellular endocrinology 29 25600632
2013 Maldevelopment of dermal lymphatics in Wnt5a-knockout-mice. Developmental biology 29 23850867
2010 Genetic interaction between Lrp6 and Wnt5a during mouse development. Developmental dynamics : an official publication of the American Association of Anatomists 29 19795512
2015 Wnt5a attenuates Wnt3a-induced alkaline phosphatase expression in dental follicle cells. Experimental cell research 28 26112214
2020 Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity. Cancer research 27 33262126
2019 LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4α/AMPK/WNT5A signaling pathway. Hematological oncology 27 31325181
2017 Bivalent Histone Codes on WNT5A during Odontogenic Differentiation. Journal of dental research 27 28880717
2014 IL-1β mediates MCP-1 induction by Wnt5a in gastric cancer cells. BMC cancer 26 24993819
2010 Expression of Wnt5a in tooth germs and the related signal transduction analysis. Archives of oral biology 26 20034610
2007 Expression of Wnt5A and Wnt10B in non-immortalized breast cancer cells. Oncology reports 26 17342334
2023 PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression. Cell death & disease 25 37173306
2014 WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells. Hepatobiliary & pancreatic diseases international : HBPD INT 25 25308364
2022 A neuron-to-astrocyte Wnt5a signal governs astrogliosis during HIV-associated pain pathogenesis. Brain : a journal of neurology 24 35040478
2019 Sclerostin and WNT-5a gingival protein levels in chronic periodontitis and health. Journal of periodontal research 23 30982988
2009 WNT5A expression in ameloblastoma and its roles in regulating enamel epithelium tumorigenic behaviors. The American journal of pathology 23 20008136
2019 miR-375 inhibits the proliferation and invasion of glioblastoma by regulating Wnt5a. Neoplasma 22 30784283
2022 Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Molecular cancer therapeutics 21 35930737
2019 Wnt5a induces ROR1 and ROR2 to activate RhoA in esophageal squamous cell carcinoma cells. Cancer management and research 21 31114334
2016 Wnt5a Signals through DVL1 to Repress Ribosomal DNA Transcription by RNA Polymerase I. PLoS genetics 21 27500936
2021 Wnt5a Promotes Lysosomal Cholesterol Egress and Protects Against Atherosclerosis. Circulation research 20 34886684
2020 Wnt5a regulates Ameloblastoma Cell Migration by modulating Mitochondrial and Cytoskeletal Dynamics. Journal of Cancer 20 32742496
2019 Wnt5a is a transcriptional target of Gli3 and Trps1 at the onset of chondrocyte hypertrophy. Developmental biology 20 31550480
2015 Wnt5a, Ryk and Ror2 expression in glioblastoma subgroups. Pathology, research and practice 20 26596412
2014 Regulation of neovascularization by S-glutathionylation via the Wnt5a/sFlt-1 pathway. Biochemical Society transactions 20 25399587
2022 Microglial WNT5A supports dendritic spines maturation and neuronal firing. Brain, behavior, and immunity 19 36395958
2019 STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. Journal of immunology (Baltimore, Md. : 1950) 19 31645416
2016 Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility. BMC cancer 19 27876017
2022 Development of opioid-induced hyperalgesia depends on reactive astrocytes controlled by Wnt5a signaling. Molecular psychiatry 18 36203006
2021 A nerve conduit filled with Wnt5a-loaded fibrin hydrogels promotes peripheral nerve regeneration. CNS neuroscience & therapeutics 18 34729936
2017 The secreted protein WNT5A regulates condylar chondrocyte proliferation, hypertrophy and migration. Archives of oral biology 18 28647646
2016 Interaction of Wnt5a with Notch1 is Critical for the Pathogenesis of Psoriasis. Annals of dermatology 18 26848218
2016 Multiple Roles of WNT5A in Breast Cancer. Medical science monitor : international medical journal of experimental and clinical research 18 28005837
2023 FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC. Cell death & disease 17 37914721
2020 Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells. Molecular medicine reports 17 33200805